| Symbol | NERV |
|---|---|
| Name | MINERVA NEUROSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1500 DISTRICT AVENUE, BURLINGTON, MA 01803 |
| Telephone | 617-600-7373 |
| Fax | — |
| — | |
| Website | https://www.minervaneurosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001598646 |
| Description | Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat patients suffering from central nervous system diseases. Minerva is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop MIN-301 for the treatment of Parkinsons disease. Minerva co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder.Minerva has not received any regulatory approvals to commercialize its product candidates and has not generated any revenue from the sales or license of any product candidates. Minerva has incurred significant operating losses since inception and expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future in connection with clinical and regulatory activities. Additional info from NASDAQ: |
Ahlholm Frederick W 🟢 acquired 680.0K shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 ($3.2M) Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreLuthringer Remy 🟢 acquired 1.7M shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 ($7.9M) Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreKupfer David 🟢 acquired 50.0K shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreKaul Inderjit 🟢 acquired 50.0K shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 Transaction Date: Jun 03, 2026 | Filing ID: 000004
Read moreVAN HEEK G JAN 🟢 acquired 50.0K shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read moreHASLER HANS PETER 🟢 acquired 50.0K shares (1 derivative) of Minerva Neurosciences, Inc. (NERV) at $4.68 Transaction Date: Jun 03, 2026 | Filing ID: 000002
Read more(99% Neutral) MINERVA NEUROSCIENCES, INC. (NERV) Announces Regulatory Update
Read moreMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Read more(10% Negative) MINERVA NEUROSCIENCES, INC. (NERV) Announces Clinical Trial Timeline Adjustment
Read moreNew Form 424B5 - Minerva Neurosciences, Inc. <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001193125-26-241915 <b>Size:</b> 517 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07565428 | Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Ne… | Phase3 | Negative Symptoms of Schizophrenia | Recruiting | 2026-04-23 | 2028-12-01 | ClinicalTrials.gov |
| NCT06107803 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokin… | Phase1 | Negative Symptoms in Schizophrenia | Completed | 2023-10-13 | 2024-01-12 | ClinicalTrials.gov |
| NCT03446846 | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With M… | Phase2 | Major Depressive Disorder | Completed | 2018-03-30 | 2019-12-13 | ClinicalTrials.gov |
| NCT03397134 | Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patien… | Phase3 | Negative Symptoms of Schizophrenia | Completed | 2017-12-15 | 2021-02-15 | ClinicalTrials.gov |
| NCT03072056 | A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to C… | Phase1 | Healthy Subjects | Completed | 2017-01-09 | 2017-07-07 | ClinicalTrials.gov |
| NCT03038646 | A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Hea… | Phase1 | Healthy Subjects | Completed | 2016-11-30 | 2017-04-20 | ClinicalTrials.gov |
| NCT02232529 | Pharmacokinetic Study of MIN-101 in Healthy Subjects | Phase1 | Schizophrenia | Completed | 2014-09-01 | 2015-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| olanzapine | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| aripiprazole | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| risperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Roluperidone | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | RECRUITING | NCT07565428 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02232529 |
| MIN-101 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02232529 |
| MIN-101 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03072056 |
| MIN-101 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03038646 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03446846 |
| MIN-117 2.5 mg | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03446846 |
| MIN-117 5.0 mg | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03446846 |
| Roluperidone 64 mg | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | COMPLETED | NCT03397134 |
| Roluperidone 32 mg | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | COMPLETED | NCT03397134 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | COMPLETED | NCT03397134 |
| Olanzapine 10 MG | Other | Phase PHASE1 | Negative Symptoms in Schizophrenia | COMPLETED | NCT06107803 |
| Roluperidone 64 mg | Other | Phase PHASE1 | Negative Symptoms in Schizophrenia | COMPLETED | NCT06107803 |